US FDA Sterile Facility Design and Cleanroom Classification

In short: This guide explains how facility layout, air systems, equipment and monitoring support aseptic processing of sterile medicines. It separates enforceable US CGMP regulations from the nonbinding recommendations and older classification table in FDA’s 2004 guidance.

Scope and source context

FDA’s Sterile Drug Products Produced by Aseptic Processing — Current Good Manufacturing Practice is a final guidance document issued in 2004. FDA’s page still lists that final version. The guidance describes FDA’s thinking on how firms can meet 21 CFR Parts 210 and 211; it is nonbinding, and it says that alternative approaches may be used if they meet applicable statutory and regulatory requirements. The regulations are the legal requirements. The recommendations and table below should be read in that context.

This article focuses on aseptic processing, where separately sterilized product, containers and closures are brought together without a final sterilization step in the sealed container. FDA’s guidance treats facility design as one element of the controls needed to protect exposed sterile product. For related reading, see production of sterile pharmaceutical products, supporting clean areas and separation in aseptic manufacturing and the FDA aseptic-processing guidance overview.

Facility layout and environmental controls

Under 21 CFR §211.42(b) and (c), buildings and workflows must support orderly operations and prevent contamination or mix-ups. For aseptic processing, §211.42(c)(10) lists features that may be appropriate, including cleanable room surfaces, temperature and humidity controls, filtered air under positive pressure, environmental monitoring, cleaning and disinfection systems, and maintenance of equipment that controls aseptic conditions.

Section 211.46 requires adequate ventilation and, where appropriate, equipment to control air pressure, microorganisms, dust, humidity and temperature. It also addresses filtration and control of contaminants in production air. These rules do not mean that every room needs identical controls; facility design should match the product, exposed materials, process and operation.

Equipment must be suitably designed, sized and located to support its intended use, cleaning and maintenance (21 CFR §211.63). Equipment cleaning and maintenance must follow written procedures and occur at appropriate intervals (21 CFR §211.67). For product-contact surfaces, 21 CFR §211.65(a) addresses materials that could alter a drug product’s safety, identity, strength, quality or purity.

For sterile products, §211.113(b) requires written procedures designed to prevent microbiological contamination and validation of all aseptic and sterilization processes. The qualification and monitoring programme should document the conditions under which the facility and process operate.

Critical zone and supporting areas

The critical zone is where exposed sterile product, containers or closures are handled. FDA’s 2004 guidance uses the Class 100 (ISO 5) designation for the critical area and recommends assessing air quality near the highest-risk exposure points during operations. It recommends evaluating airflow under dynamic conditions, including personnel, equipment and routine interventions.

The same guidance recommends HEPA-filtered air and airflow sufficient to sweep particles away from exposed product. It says the velocity should be justified for each processing line. A footnote reports that 0.45 m/s (90 ft/min), with a range of ±20% around the setpoint, had generally been established; it also says higher velocities may be appropriate for operations that generate more particles. Treat these as recommendations from the 2004 guidance, not universal regulatory limits.

FDA’s table describes the following air classifications and recommended microbiological action levels. The classifications were measured near exposed articles during activity. The FDA guidance allows alternative microbiological action levels where the operation or analytical method supports them, and describes settling plates as optional.

• FDA says samples from Class 100 (ISO 5) environments should normally have no microbiological contaminants.

This is the table in FDA’s 2004 guidance; its action levels are recommendations rather than statutory limits. Do not adopt them as site acceptance criteria without assessing the process, sampling method, current regulatory expectations and the site’s documented contamination control strategy.

FDA’s 2004 guidance describes ISO 5 as approximately equivalent to EU Grade A. The current EU GMP Annex 1 (2022 revision, fully applicable since 25 August 2024) sets out its own cleanroom classification, including measurements at rest and in simulated operations, and separate requirements for microbial qualification and routine monitoring. A simple label-to-label comparison does not replace applying the requirements that govern the product and site.

Qualification, monitoring and records

Qualification should include conditions representative of routine activity, not only an empty room. FDA’s guidance recommends monitoring the critical area during each production shift and placing particle probes where they best assess risk to exposed product. It also recommends documenting airflow visualisation under dynamic conditions and considering interventions and equipment configuration. These are guidance recommendations; the study design should be justified for the facility.

Routine environmental and process monitoring should use justified locations, methods, alert/action levels and responses. Trends and excursions need review under the approved quality system. EU GMP Annex 1, §§4.27–4.29 and 9.7, gives the EU framework for cleanroom classification and monitoring; its requirements should be applied where relevant rather than substituted with the FDA 2004 table.

Retain GMP records associated with a product batch for at least 1 year after the expiry date of the respective batch. EU GMP Part I Chapter 4 §4.11 also requires at least 5 years after Qualified Person certification when that period is longer; 21 CFR §211.180(a) sets the US minimum for records specifically associated with a drug-product batch. Retain records longer when local law or the marketing authorization requires it.

Frequently asked questions

Are the FDA 2004 table values mandatory limits?

No. The FDA document is guidance and identifies the microbiological values as recommended action levels. The enforceable requirements are in the applicable regulations; a site should justify its own monitoring programme and criteria.

Does ISO 5 automatically mean EU Grade A?

FDA’s 2004 guidance describes them as approximately equivalent, but current EU GMP Annex 1 has its own classification states and microbial requirements. Use the rules that apply to the site and product; do not rely on a label comparison alone.

Does every aseptic room need the same pressure, airflow or monitoring settings?

No single setting is stated for every room in the cited regulations. The facility and monitoring controls must be appropriate to the product and operation, and any guidance recommendations should be justified for the actual process.

References

• U.S. Food and Drug Administration (FDA), Guidance for Industry: Sterile Drug Products Produced by Aseptic Processing — Current Good Manufacturing Practice, final guidance, 2004: FDA guidance page and official PDF.
• United States, 21 CFR Part 211, §§211.42, 211.46, 211.63, 211.65(a), 211.67 and 211.113(b), current eCFR accessed 16 October 2026: Part 211.
• European Commission, EudraLex Volume 4, Annex 1, Manufacture of Sterile Medicinal Products, 2022 revision, fully applicable since 25 August 2024: official PDF.
• European Commission, EudraLex Volume 4, Part I, Chapter 4, Documentation, Revision 1 (January 2011), §4.11: official PDF.
• United States, 21 CFR §211.180(a), General requirements, current eCFR accessed 16 October 2026: official regulation.